Daxocox, for the treatment of pain and inflammation associated with osteoarthritis in dogs, 4 tablets

Daxocox is a product used for the treatment of pain and inflammation associated with osteoarthritis in dogs.

Ingredients:
Active substance – Enflicoxib 45 mg
Excipients – Black iron oxide (E172) 0.26%, Yellow iron oxide (E172) 0.45%, Red iron oxide (E172) 0.5%.

Ingredients:
Active substance – Enflicoxib 70 mg
Excipients – Black iron oxide (E172) 0.26%, Yellow iron oxide (E172) 0.45%, Red iron oxide (E172) 0.5%.

Key benefits:
Enflicoxib is a non-steroidal anti-inflammatory drug of the coxib class and works by selectively inhibiting the enzyme cyclooxygenase-2.
Enflicoxib is well absorbed after oral administration, bioavailability is high and increased by 40-50% by the presence of food.

Intended for:
Dogs.

Method of administration:
Oral administration.

Presentation form:
Box of 4 tablets.

Dosage:
The dosing interval is once a week.
First dose: 8 mg Enflicoxib per kg body weight.
Maintenance dose: repeat treatment every 7 days with a dose of 4 mg Enflicoxib per kg body weight.

Possible adverse effects:
Vomiting, soft faeces and/or diarrhoea have been commonly reported in clinical trials, but most cases recovered without treatment.
In less common cases, apathy, loss of appetite and haemorrhagic diarrhoea have been reported. Gastrointestinal ulceration has been reported in rare cases.
Elevated blood urea and serum cholesterol levels were observed at the recommended dose in young, healthy dogs in a laboratory safety study.

Precautions:
As the safety of this medicinal product has not been fully demonstrated in very young animals, close monitoring is recommended during treatment of young dogs less than 6 months of age.
Use this product under strict veterinary supervision if there is a risk of gastrointestinal ulceration or if the animal has previously shown intolerance to NSAIDs.

Storage:
Store in a dry place away from moisture and direct sunlight, at temperatures up to 25°C.

In case of overdose:
In overdose safety studies, with continuous weekly administration of 12 mg/kg body weight for a period of 7 months and 20 mg/kg body weight for a period of 3 months, with an initial loading dose, elevated blood urea and serum cholesterol levels were observed.
No other treatment-related effects were detected.